Continued strong order growth

• Q3 2021 orders CHF 132.8m, YoY +21.0% organic
• Enlarged institutional investor base with Fidelity (US), Capital Research (US) and UBS Asset Management (CH) above 3% threshold
• Full year outlook confirmed

As medmix’ orders will be reported by Sulzer in its Q3 2021 reporting as discontinued operations, medmix exceptionally publishes order intake outside its routine half year reporting frame.

In the first nine months of 2021, order intake increased by CHF 146.9m to CHF 401.6m compared to the same period a year ago, + 58.3% currency-adjusted and + 41.3% organic.

Q3 2021 orders were at CHF 132.8m, up 21.0% organically year on year and up 14.0% organically versus 2019 (pre-pandemic). Although historically Q3 is seasonally lower, 2021 Q3 orders remained in line with our H1 2021 run rate. Healthcare and Industry segments performed strongly, with Beauty showing a rebound.

Since the listing of the medmix shares at SIX Swiss Exchange on September 30, 2021, the following investors have crossed the notification threshold of 3% of total shareholding:

• Fidelity (5.1%)
• Capital Research (5.0%)
• UBS Asset Management (3.6%)

Tiwel Holding did not participate in the capital increase and holds 40.5% of the capital.

We are on track to meet our full year 2021 targets of around 25.0% profitability (adj. EBITDA margin) on revenues of around CHF 450m.

medmix is a global leader in high-precision delivery devices. We occupy leading positions in the healthcare, consumer and industrial end-markets. Our customers benefit from a dedication to innovation and technological advancement that has resulted in over 900 active patents. Our 12 production sites worldwide together with our highly motivated and experienced team of 1’900 employees provide our customers with uncompromising quality, proximity and agility. medmix is headquartered in Baar, Switzerland. Our shares are traded on the SIX Swiss Exchange (SIX: MEDX). www.medmix.swiss